Sulfonamide allergy label and the risk of opportunistic infections in solid organ transplant recipients – A retrospective matched cohort study
Transplant Infectious Disease · 2024
DOI: 10.1111/tid.14355 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Transplant Infectious Disease, 2024. Verfasst von Taha Al-Shaikhly und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Section of Allergy, Allergy & Immunology, Penn State College of Medicine, Hershey, Pennsylvania, USA. Hauptthemen laut MEDLINE: Organ Transplantation, Opportunistic Infections, Sulfonamides, Drug Hypersensitivity. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCATS NIH HHS, NIH HHS, National Center for Advancing Translational Sciences.
Abstract (Originalsprache)
Background
While a penicillin allergy label has been linked to various negative clinical outcomes, limited studies have specifically characterized the implication of sulfonamide allergy labels (SAL) on clinical outcomes. We examined the impact of SAL on clinical outcomes of solid organ transplant recipients.
Methods
In this retrospective matched cohort study, we utilized the TriNetX US collaborative Network, a multicenter de‐identified US database, and identified solid organ transplant recipients with and without SAL. The 1‐year probability of developing Pneumocystis jirovecii pneumonia (PJP), toxoplasmosis, and nocardiosis was estimated and contrasted between the two study groups. The hazard ratio (HR) and the 95% confidence interval (CI) quantified the strength and direction of the association between SAL and these outcomes.
Results
When comparing 1571 solid organ transplant recipients with SAL to an equal number of matched controls, patients with SAL had a higher probability of developing nocardiosis (HR 3.85; 95% CI, 1.44–10.30; p = .004; corrected p = .04), and toxoplasmosis (HR, 1.87; 95% CI, 1.10–3.17; p = .019; corrected p = .19), but no difference in the risk of developing PJP (HR, 1.64; 95% CI, 0.68–3.95; p = .27). There was no mortality difference (HR, 1.31; 95% CI, 0.99–1.75; p = .061; corrected p = .6). SAL influenced antibiotic prescription with overutilization of dapsone, atovaquone, and pentamidine and underutilization of trimethoprim and sulfamethoxazole.
Conclusion
SAL is associated with an increased risk of opportunistic infections following solid organ transplantation. Measures to evaluate and de‐label sulfonamide allergy prior to transplantation or desensitizing shortly after transplantation are advisable. image
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Section of Allergy, Allergy & Immunology, Penn State College of Medicine, Hershey, Pennsylvania, USA.
- Department of Medicine, Division of Hospital Medicine, Penn State College of Medicine, Hershey, Pennsylvania, USA.
- Department of Public Health Sciences, Penn State College of Medicine, Hershey, Pennsylvania, USA.
ORCID-Profile: Taha Al-Shaikhly
Förderung
- NCATS NIH HHS
- NIH HHS
- National Center for Advancing Translational Sciences
- National Institutes of Health
Zitieren
APA
Al-Shaikhly, T., Al-Obaydi, S., Craig, T. J., & Henao, M. P. (2024). Sulfonamide allergy label and the risk of opportunistic infections in solid organ transplant recipients – A retrospective matched cohort study. Transplant Infectious Disease. https://doi.org/10.1111/tid.14355
Vancouver
Al-Shaikhly T, Al-Obaydi S, Craig TJ, Henao MP. Sulfonamide allergy label and the risk of opportunistic infections in solid organ transplant recipients – A retrospective matched cohort study. Transplant Infectious Disease. 2024. doi:10.1111/tid.14355
BibTeX
@article{AlShaikhly2024,
author = {Al-Shaikhly, Taha and Al-Obaydi, Sarah and Craig, Timothy J and Henao, Maria P},
title = {Sulfonamide allergy label and the risk of opportunistic infections in solid organ transplant recipients – A retrospective matched cohort study},
journal = {Transplant Infectious Disease},
year = {2024},
doi = {10.1111/tid.14355}
}
EUVIMED